Delivery Order SPE2DB24D9223-SPE2DB25FKEEF
Award Date
4/7/25
Potential Completion Date
4/8/25
Potential Value
$4.3K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of 4,557,611,040 capsules of the drug XTANDI 40 MG, with a total ceiling value of $77,787.00. The contract has an ultimate completion date of June 23, 2022 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a significant $499,999,999...
This is a firm fixed-price delivery order for pharmaceutical products and medical supplies awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The $16,678.36 contract covers the delivery of XTANDI 40 MG TABLET 120S to military healthcare facilities through March 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $12,934.05 contract is for the delivery of 120 capsules of the prescription drug Xtandi 40 mg by April 2, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a range of pharmaceutical...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,311.35 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product, to support the medical supply needs of military health facilities. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $12,934.05 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product, to support the medical supply needs of military health facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This is a $4,311.35 firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA). The order is for 120 capsules of the drug Xtandi 40 mg. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a range of pharmaceutical products to support the medical supply needs of military health facilities...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business. The contract is valued at $4,311.35 and has an ultimate completion date of April 4, 2024. It is an order against DMS Pharmaceutical Group's indefinite delivery vehicle (IDV) contract SPE2DB, valued up to $4,999,999 through 2025, which enables DLA to issue delivery orders for a broad range of pharmaceutical items to fulfill the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $4,169.59, is for the delivery of 4567828655 - XTANDI 80 MG TABLET 60S to the DLA. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm fixed-price delivery orders for a wide...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $76,753.74 contract is for the delivery of 120 capsules of the prescription drug XTANDI 40 MG. The award has an ultimate completion date of May 19, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the provision of XTANDI 40 mg capsules. The contract, valued at $25,868.10, has an ultimate completion date of May 6, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which allows the DLA to issue delivery...